Naoto Takase

Takarazuka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED).

Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED).

Journal: Therapeutic advances in medical oncology

Published: February 07, 2025

Efficacy of EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry).

Efficacy of EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: January 13, 2025

Case of a Pleomorphic Carcinoma Successfully Treated with Nivolumab and Ipilimumab

Case of a Pleomorphic Carcinoma Successfully Treated with Nivolumab and Ipilimumab

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: December 25, 2024

Correction: Successful surgical treatment for primary cardiac angiosarcoma: a case report.

Correction: Successful surgical treatment for primary cardiac angiosarcoma: a case report.

Journal: General thoracic and cardiovascular surgery cases

Published: November 09, 2024

Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study.

Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: April 20, 2024

Association between Immune-Related Adverse Events and Atezolizumab in Previously Treated Patients with Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.

Association between Immune-Related Adverse Events and Atezolizumab in Previously Treated Patients with Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.

Journal: Cancer research communications

Published: April 08, 2024

Comprehensive serum biomarker analysis reveals IL-8 changes as the only predictor of the effectiveness of immune checkpoint inhibitors for patients with advanced non-small cell lung cancer.

Comprehensive serum biomarker analysis reveals IL-8 changes as the only predictor of the effectiveness of immune checkpoint inhibitors for patients with advanced non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: March 26, 2024

Trial Protocol of a Phase II Study of mFOLFOXIRI after Metastasectomy in Patients with Oligometastatic Colorectal Cancer (FANTASTIC Study).

Trial Protocol of a Phase II Study of mFOLFOXIRI after Metastasectomy in Patients with Oligometastatic Colorectal Cancer (FANTASTIC Study).

Journal: Journal of the anus, rectum and colon

Published: March 21, 2024

Monitoring ctDNA RAS Mutational Status in Metastatic Colorectal Cancer: A Trial Protocol of RAS-trace and RAS-trace-2 Studies.

Monitoring ctDNA RAS Mutational Status in Metastatic Colorectal Cancer: A Trial Protocol of RAS-trace and RAS-trace-2 Studies.

Journal: Journal of the anus, rectum and colon

Published: September 20, 2023

Successful surgical treatment for primary cardiac angiosarcoma: a case report.

Successful surgical treatment for primary cardiac angiosarcoma: a case report.

Journal: General thoracic and cardiovascular surgery cases

Published: May 03, 2023

Randomized phase II study of zoledronate dosing every four versus eight weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312).

Randomized phase II study of zoledronate dosing every four versus eight weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 03, 2022

Pharmacokinetics and clinical outcomes of nivolumab administered every 4 weeks in patients with advanced non-small-cell lung cancer: A four-case pilot study.

Pharmacokinetics and clinical outcomes of nivolumab administered every 4 weeks in patients with advanced non-small-cell lung cancer: A four-case pilot study.

Journal: Respiratory investigation

Published: October 19, 2020

Showing 1-12 of 15

Last Updated: 09/26/2026